Phase 2 Study of SPI-2012 or Pegfilgrastim for the Management of Neutropenia in Participants With Breast Cancer

NCT01724866 · clinicaltrials.gov ↗

PHASE2

Phase

COMPLETED

Status

148

Enrollment

INDUSTRY

Sponsor class

Conditions

Neutropenia

Interventions

DRUG: SPI-2012
DRUG: Pegfilgrastim
DRUG: Docetaxel
DRUG: Cyclophosphamide

Sponsor

Spectrum Pharmaceuticals, Inc